Scienture Holdings, Inc. (SCNX)
| Market Cap | 15.51M +40.3% |
| Revenue (ttm) | 477,676 +225.2% |
| Net Income | -41.85M |
| EPS | -1.81 |
| Shares Out | 40.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 995,171 |
| Open | 0.4120 |
| Previous Close | 0.3878 |
| Day's Range | 0.3818 - 0.4269 |
| 52-Week Range | 0.2382 - 2.6000 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 1.50 (+292.88%) |
| Earnings Date | May 15, 2026 |
About SCNX
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It al... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for SCNX stock is "Buy" and the 12-month stock price target is $1.5.
News
Scienture announces progress in commercialization of Arbli
Scienture (SCNX) announced significant progress in the commercialization of Arbli, including expanded payor coverage, broader pharmacy access, new channel partnerships, and ongoing initiatives designe...
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value...
Scienture reveives U.S. patent covering Rezenopy Nasal Spray
Scienture (SCNX) announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,622,903 B2, patent covering Rezenopy Nasal Spray 10 mg, effective May 12, with an…
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existin...
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing ...
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment
Scienture announces third patent granted for Arbli
Scienture (SCNX) announced that the United States Patent and Trademark Office has granted its third patent covering Arbli oral suspension, the first and only FDA-approved ready-to-use oral liquid form...
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI ™ as the first FDA-approved ready-to-use oral suspension
Scienture granted 180-day extension to meet Nasdaq minimum bid price
Scienture (SCNX) Holdings announced it received notification from Nasdaq approving the company’s request for an additional 180-calendar day extension to regain compliance with the minimum closing bid ...
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for exist...
Why Is Scienture Holdings Stock (SCNX) Up Today?
Scienture Holdings stock rallied after the company revealed new purchase order agreements.
Scienture formalized multiple GPO agreements for Rezenopy
Scienture (SCNX) announced that it has formalized multiple commercial Group Purchasing Organization, GPO, agreements for Rezenopy Nasal Spray 10 mg, providing access to more than 5000 healthcare insti...
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers
Scienture initiated with a Buy at Maxim
Maxim initiated coverage of Scienture (SCNX) with a Buy rating and $1.50 price target
Scienture initiated with a Buy at Maxim
Maxim initiated coverage of Scienture (SCNX) with a Buy rating and $1.50 price target
Scienture provides commercial update on Arbli
Scienture (SCNX) provided a commercial update on Arbli oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, fina...
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 millio...
Scienture announces USPTO issues patent covering REZENOPY Nasal Spray
Scienture (SCNX) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY Nasal Spray 10 mg, effe...
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existin...
Scienture provides update on commercial launch of REZENOPY
Scienture (SCNX) provided an update on the commercial launch of REZENOPY. As previously disclosed, Scienture, a wholly owned subsidiary of Scienture Holdings, entered into a definitive agreement with ...
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existin...
Scienture, BlinkRx announce strategic collaboration to expand access to Arbli
Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be...
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned ph...